Crispr Therapeutics Sees Unusually Large Options Volume (CRSP)

Crispr Therapeutics AG (NASDAQ:CRSP) was the recipient of unusually large options trading on Thursday. Stock investors acquired 1,168 put options on the company. This represents an increase of 1,986% compared to the typical volume of 56 put options.

Several analysts have recently commented on the company. Oppenheimer assumed coverage on Crispr Therapeutics in a research note on Thursday, December 7th. They issued a “hold” rating for the company. BidaskClub upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Piper Jaffray Companies assumed coverage on Crispr Therapeutics in a research note on Friday, December 22nd. They issued an “overweight” rating for the company. SunTrust Banks restated a “hold” rating and issued a $16.00 target price on shares of Crispr Therapeutics in a research note on Friday, November 10th. Finally, Cann restated a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, November 9th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and a consensus target price of $22.38.

In other news, insider Tyler Dylan-Hyde sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $18.90, for a total value of $283,500.00. Following the completion of the sale, the insider now directly owns 130,204 shares in the company, valued at approximately $2,460,855.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $18.98, for a total value of $21,114,225.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,076,167 shares of company stock valued at $40,049,167. Company insiders own 39.98% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN lifted its position in Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares in the last quarter. Capital Investment Advisory Services LLC bought a new position in Crispr Therapeutics in the 3rd quarter valued at about $193,000. Ark Investment Management LLC bought a new position in Crispr Therapeutics in the 2nd quarter valued at about $206,000. Moloney Securities Asset Management LLC bought a new position in Crispr Therapeutics in the 3rd quarter valued at about $235,000. Finally, Bank of New York Mellon Corp bought a new position in Crispr Therapeutics in the 3rd quarter valued at about $288,000. 24.52% of the stock is currently owned by institutional investors and hedge funds.

Crispr Therapeutics (NASDAQ CRSP) opened at $26.81 on Friday. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $28.50. The firm has a market cap of $1,230.00 and a PE ratio of -83.78.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.02). Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The business had revenue of $2.39 million during the quarter, compared to the consensus estimate of $3.61 million. During the same period in the previous year, the business posted ($2.77) EPS. Crispr Therapeutics’s revenue was up 54.2% compared to the same quarter last year. equities analysts predict that Crispr Therapeutics will post -2.46 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/07/crispr-therapeutics-sees-unusually-large-options-volume-crsp.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply